HOOK · HOOKIPA Pharma Inc.
$1.15
At close · Jun 2
Going-concern doubt
— flagged May 15, 2025
Substantial doubt about the company's ability to continue as a going concern.
“As of the filing date of this Quarterly Report on Form 10-Q, the Company's expectation to generate negative operating cash flows in the future and the need for additional funding to support its planned operations raise substantial doubt regarding the Company's ability to continue as a going concern for a period of one year after the date that these condensed consolidated financial statements are issued.”View the 10-Q filed May 15, 2025
Market Cap
$14.02M
Shares
12.19M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$43.95M
+118.3%
FY2024
Net Income
-$43.5M
+46.7%
FY2024
Operating Margin
-117.09%
+368.2pp
FY2024
Diluted EPS
-$3.47
+59.8%
FY2024
Operating Cash Flow
-$76.98M
-33.8%
FY2024
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| $9.35M | $43.95M | $20.13M | $14.25M | $18.45M | $19.58M | $11.94M | $7.63M | — | |
| $61.2M | $68.51M | $86.42M | $68.65M | $82.85M | $54.79M | $46.31M | $21.97M | $9.77M | |
| $23.06M | $20.23M | $18.63M | $18.76M | $17.27M | $18.08M | $16.72M | $6.84M | $4.39M | |
| — | $2.75M | $3.55M | $3.6M | $4.64M | $4.15M | $3.07M | $640K | — | |
| $2.83M | $2.66M | — | — | — | — | — | — | — | |
| $89.79M | $95.4M | $117.82M | $87.4M | $100.12M | $72.87M | $63.03M | $28.81M | $14.16M | |
| -$80.44M | -$51.46M | -$97.69M | -$73.16M | -$81.67M | -$53.29M | -$51.09M | -$21.18M | -$14.16M | |
| — | -117.09% | -485.34% | -513.4% | -442.73% | -272.08% | -427.78% | -277.62% | — | |
| — | -$48.7M | -$94.14M | -$69.55M | -$77.03M | -$49.14M | -$48.02M | -$20.54M | — | |
| — | $2000 | $317K | $687K | $898K | $786K | $877K | $778K | $606K | |
| $2.61M | $3.7M | $5.29M | $1.63M | $27K | $400K | $1.59M | $0 | — | |
| $7.02M | $7.85M | $16.48M | $8.47M | $6.01M | $9.2M | $8.05M | $4.97M | $1.44M | |
| -$73.42M | -$43.61M | -$81.21M | -$64.69M | -$75.66M | -$44.08M | -$43.04M | -$16.21M | -$12.72M | |
| -$106K | -$106K | $368K | $230K | $1000 | $0 | $0 | $24K | $4000 | |
| -$73.31M | -$43.5M | -$81.58M | -$64.92M | -$75.67M | -$44.08M | -$43.04M | -$16.24M | -$12.72M | |
| — | -98.99% | -405.29% | -455.58% | -410.15% | -225.09% | -360.38% | -212.83% | — | |
| -$72.35M | -$40.66M | -$82.36M | -$67.29M | -$74.38M | -$45.5M | -$43.97M | -$18.6M | -$10.96M | |
| USD/shares | — | -$3.47 | -$8.63 | -$9.91 | -$23.00 | -$16.90 | -$24.10 | — | — |
| USD/shares | — | -$3.47 | -$8.63 | -$9.91 | -$23.00 | -$16.90 | -$24.10 | — | — |
| shares | — | 12.54M | 9.45M | 6.55M | 3.28M | 2.6M | 1.79M | 91.44K | 91.18K |
| shares | — | 12.54M | 9.45M | 6.55M | 3.28M | 2.6M | 1.79M | 91.44K | 91.18K |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2024 | FY2023 | FY2022 |
|---|---|---|---|
| Single Reportable Segment | $43,946,000 | $20,129,000 | $14,249,000 |
By Product & Service (USD)
| Component | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|
| Grant | $300,000 | $600,000 | $800,000 | $700,000 | $800,000 |
Key facts
CIK
1760542
CUSIP
43906K209